Status:

TERMINATED

Continuous Vs Single Shot Block After ACL

Lead Sponsor:

Northwell Health

Conditions:

ACL Injury

Eligibility:

All Genders

16+ years

Phase:

EARLY_PHASE1

Brief Summary

The investigators will be randomizing patients to either receive an adductor canal block in the operating room postoperatively as single shot of 20-30cc bupivacaine or to have a catheter inserted into...

Detailed Description

Screening evaluation will occur during the preoperative visit prior to surgery which generally occurs within 28 days prior to surgery. No separate screening is indicated in this study. Patients will ...

Eligibility Criteria

Inclusion

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged \>16 years old
  • In good general health as evidenced by medical history and deemed medically healthy enough to tolerate surgery by the patient's primary care physician
  • MRI with evidence of ACL tear, and wanting to have an ACL reconstruction surgery
  • Ability to take oral medication and be willing to adhere to the study intervention, including telephone calls
  • Agrees to complete surveys required on the days specified between 5-9PM

Exclusion

  • Current daily opioid requirement exceeding the equivalent of 15mg morphine
  • Daily prescription of corticosteroid, tricyclic antidepressant, gabapentin, or tramadol
  • Carrying the diagnosis of chronic pain syndrome, uncontrolled anxiety, history of schizophrenia or related psychiatric disorders
  • History of alcohol or drug abuse/addiction
  • History of preexisting nerve damage in the surgical extremity
  • Knee surgery (same knee) in the previous 12 weeks
  • Anticipated knee surgery in the other knee planned in the ensuing 6 months
  • Diabetic patients with blood sugar values exceeding 250 mg/dl in the previous month
  • BMI \>40Kg/m2
  • Pregnancy, which will be determined by a serum or urine HCG test on the day of surgery.
  • Incarceration
  • Inability to communicate with staff, including being unreachable by telephone
  • Revision ACL reconstruction
  • Patient reconsideration after initial agreement.
  • Non-English speaking subjects

Key Trial Info

Start Date :

September 25 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 17 2022

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT04101682

Start Date

September 25 2020

End Date

May 17 2022

Last Update

October 18 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Plainview Hospital

Plainview, New York, United States, 11803